GlassScriptPhysician profile
John Taylor Moore
NPI 1669615225
$19,253.92
in general payments reported to CMS, 2019-2025
32 companies · $12K in 2025
The $12K reported for 2025 was more than what 95% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $1,110 · 2021: $1,292 · 2022: $1,205 · 2023: $1,924 · 2024: $1,255 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $6,167 · Travel and Lodging: $4,660 · Food and Beverage: $4,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $6,166.67 |
| Travel and Lodging | $4,660.02 |
| Food and Beverage | $4,137.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $9,405.51 | 2025 | Nanoknife, Nanoknife |
| Axonics, INC. | $2,422.94 | 2020-2024 | Axonics, Bulkamid |
| Boston Scientific Corporation | $2,007.70 | 2020-2025 | Lumenis Pulse 120h, Axonics |
| Teleflex LLC | $1,052.19 | 2023-2024 | Urolift |
| Astellas Pharma US INC | $671.52 | 2019-2022 | |
| Allergan, INC. | $405.38 | 2019-2022 | |
| Abbvie INC. | $401.10 | 2019-2025 | |
| Medtronic USA, INC. | $333.38 | 2019-2020 | |
| Agiliti Surgical, INC. | $284.61 | 2025 | Sonablate Hifu, Koelis Trinity Mri/US Fusion |
| Pfizer INC. | $277.91 | 2019-2023 | |
| Janssen Biotech, INC. | $265.67 | 2019-2025 | Erleada, Balversa |
| Novartis Pharmaceuticals Corporation | $199.68 | 2023-2025 | |
| Myovant Sciences INC. | $187.47 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $164.56 | 2019-2023 | Provenge |
| Profound Medical Corp. | $143.38 | 2025 | Tulsa-Pro |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valencia Technologies Corporation | $125.91 | 2023 | Ecoin Device Kit |
| Amgen INC. | $105.59 | 2019-2022 | |
| Tolmar, INC. | $101.25 | 2023 | |
| Medtronic, INC. | $98.75 | 2021-2025 | Interstim |
| Urogen Pharma, INC. | $86.50 | 2021-2023 | Jelmyto |
| Blue Earth Diagnostics | $83.59 | 2020-2023 | |
| Myriad Genetic Laboratories, INC. | $83.28 | 2020-2023 | Prolaris |
| Antares Pharma, INC. | $82.99 | 2022 | |
| Merck Sharp & Dohme LLC | $53.38 | 2022-2025 | Keytruda, Lynparza |
| Sumitomo Pharma America, INC. | $53.22 | 2023 | Gemtesa, Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $51.42 | 2022 | |
| Ferring Pharmaceuticals INC. | $49.09 | 2019-2020 | |
| Travere Therapeutics, INC. | $19.39 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.23 | 2022 | |
| Endo Pharmaceuticals INC. | $17.33 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.